GeneDx (NASDAQ:WGSWW) is a molecular diagnostics company specializing in high-complexity genetic testing for rare and ultra-rare inherited disorders. The company leverages next-generation sequencing (NGS) technologies, including whole exome sequencing, targeted gene panels, and chromosomal microarray analysis, to deliver comprehensive diagnostic insights. Its services are designed to support clinicians in identifying genetic mutations that underlie pediatric and adult conditions, guiding patient management, treatment decisions, and genetic counseling.
Founded in 2000 by Dr. Stephen Kingsmore, GeneDx has built a reputation for clinical and laboratory excellence, earning accreditation from regulatory bodies and certifications in both the United States and internationally. The company's laboratory operations are based in Gaithersburg, Maryland, where a multidisciplinary team of geneticists, bioinformaticians, and laboratory scientists collaborates to refine test design, interpretation pipelines, and reporting standards. GeneDx maintains a robust database of variant interpretations, continuously updated through internal research and partnerships with academic and clinical institutions.
GeneDx serves hospitals, health systems, and physician practices across North America, Europe, and Asia, and it engages in strategic collaborations with biopharmaceutical companies to support companion diagnostic development and clinical trial enrolment. By combining advanced genomics with detailed phenotypic data, the company aims to accelerate diagnostic odysseys and enable precision medicine approaches. GeneDx’s commitment to innovation and quality positions it as a leading provider of genetic testing services in the global diagnostics landscape.
